Benzoic Acid Derivatives that are Modulators or Agonists of GlyR
申请人:Gyback Helena
公开号:US20090192190A1
公开(公告)日:2009-07-30
Compounds of formula I,
wherein R1, Z, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of using the same for therapeutic purposes and methods of making the same.
of chiral S(VI) from prochiral S(II) is a formidable challenge due to the inevitable formation of stable chiral S(IV). Previous synthetic strategies rely on the conversion of chiral S(IV) or enantioselectivedesymmetrization of preformed symmetrical S(VI) substrates. Here, we report desymmetrizingenantioselective hydrolysis of in situ-generated symmetric aza-dichlorosulfonium from sulfenamides for
[EN] BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR<br/>[FR] NOUVEAUX COMPOSES II
申请人:ASTRAZENECA AB
公开号:WO2006121390A3
公开(公告)日:2007-01-11
BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR
申请人:AstraZeneca AB
公开号:EP1890993A2
公开(公告)日:2008-02-27
N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer